Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2472-2482

  Choi, Sung Hee ^a   Kim, Byung Gyu ^a   Robinson, Janet ^a   Fink, Steve ^a   Yan, Min ^a   Sporn, Michael B ^b   Markowitz, Sanford D ^a   Letterio, John J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; AZOXYMETHANE; BARDOXOLONE METHYL; CYCLOOXYGENASE 2; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE; SMAD4 PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLITIS; COLITIS ASSOCIATED COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG SYNTHESIS; ENZYME INDUCTION; EPITHELIUM CELL; EXPERIMENTAL DISEASE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENESIS; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; ENZYME INDUCTION; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTESTINAL MUCOSA; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; OLEANOLIC ACID; SMAD4 PROTEIN; STAT TRANSCRIPTION FACTORS;

EID: 84902179818     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69672     Document Type: Article

References (54)

1. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2012;58(2):519-525.
2. [No authors listed]. Epidemiological and clinical features of Spanish patients with Crohn's disease. Spanish Epidemiological and Economic Study Group on Crohn's disease. Eur J Gastroenterol Hepatol. 1999;11(10):1121-1127.
3. Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.
4. Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012;271(5):421-428.
5. Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18(1):1-15.
6. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854-862.
7. Popivanova BK, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 2009;69(19):7884-7892.
8. Grivennikov SI1, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
9. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114 e2105.
10. Ohno H, Morikawa Y, Hirata F. Studies on 15-hydroxyprostaglandin dehydrogenase with various prosta glandin analogues. J Biochem. 1978;84(6):1485-1494.
11. Greenhough A, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377-386.
12. Myung SJ, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(32):12098-12102.
13. Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004;101(50):17468-17473.
14. Backlund MG, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280(5):3217-3223.
15. Roberts HR, Smartt HJ, Greenhough A, Moore AE, Williams AC, Paraskeva C. Colon tumour cells increase PGE (2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis. 2011;32(11):1741-1747.
16. Wolf I, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006;66(15):7818-7823.
17. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2005;26(1):65-72.
18. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101-128.
19. Calon A, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571-584.
20. Otani T, et al. Levels of NAD (+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-α. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G361-G368.
21. Dai L, Perera DS, King DW, Southwell BR, Burcher E, Liu L. Hemokinin-1 stimulates prostaglandin E (2) production in human colon through activation of cyclooxygenase-2 and inhibition of 15-hydroxyprostaglandin dehydrogenase. J Pharmacol Exp Ther. 2012;340(1):27-36.
22. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod. 2011;74(3):537-545.
23. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12(8):564-571.
24. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007;7(5):357-369.
25. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64(4):972-1003.
26. Liby K, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res. 2008;14(14):4556-4563.
27. Honda T, et al. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg Med Chem Lett. 2006;16(24):6306-6309.
28. Pareek TK, et al. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci Rep. 2011;1:201.
29. Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005;65(11):4789-4798.
30. Suh N, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999;59(2):336-341.
31. Suh N, et al. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res. 2003;63(6):1371-1376.
32. Liby K, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res. 2006;12(14 pt 1):4288-4293.
33. Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE. Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid and prostaglandin 15-deoxy-delta (12, 14) J2: a role for Smad signaling. Mol Pharmacol. 2004;65(2):309-318.
34. Kim BG, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature. 2006;441(7096):1015-1019.
35. Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Methods Mol Biol. 2009;511:193-233.
36. Ji Y, et al. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther. 2006;5(6):1452-1458.
37. To C, et al. The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex. J Biol Chem. 2008;283(17):11700-11713.
38. Na HK, Park JM, Lee HG, Lee HN, Myung SJ, Surh YJ. 15- Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol. 2011;82(10):1352-1360.
39. Liu Z, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer. Cancer Biol Ther. 2010;10(8):780-787.
40. Krishnan AV, Swami S, Feldman D. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids. 2012;77(11):1107-1112.
41. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010;17(1):R19-R38.
42. Fleming N, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73(2):725-735.
43. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. TGF-β signalling in colon carcinogenesis. Cancer Lett. 2012;314(1):1-7.
44. Tang Y, et al. Transforming growth factor-β suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res. 2005;65(10):4228-4237.
45. Eruslanov E, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol. 2009;182(12):7548-7557.
46. Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A. 2009;106(23):9409-9413.
47. Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, Stappenbeck TS. Wnt5a potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. Science. 2012;338(6103):108-113.
48. Jarry A, et al. Mucosal IL-10 and TGF-β play crucial roles in preventing LPS-driven, IFN-γ-mediated epithelial damage in human colon explants. J Clin Invest. 2008;118(3):1132-1142.
49. Yates MS, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1, 9 (11)-dien-28-oyl] imidazole. Cancer Res. 2006;66(4):2488-2494.
50. Yates MS, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6(1):154-162.
51. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol. 2005;2(10):518-525.
52. Yore MM, Kettenbach AN, Sporn MB, Gerber SA, Liby KT. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One. 2011;6(7):e22862.
53. Yang X, Li C, Herrera PL, Deng CX. Generation of Smad4/Dpc4 conditional knockout mice. Genesis. 2002;32(2):80-81.
54. Orban PC, Chui D, Marth JD. Tissue- and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci U S A. 1992;89(15):6861-6865.